|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008838,
umls-concept:C0008976,
umls-concept:C0030705,
umls-concept:C0034380,
umls-concept:C0034656,
umls-concept:C0078257,
umls-concept:C0205179,
umls-concept:C0205390,
umls-concept:C0246415,
umls-concept:C0439851,
umls-concept:C0684249,
umls-concept:C1552596,
umls-concept:C1947931
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2010-7-8
|
|
pubmed:abstractText |
Quality of life (QoL) has gained greater importance in the management of metastatic non-small-cell lung cancer due to the palliative nature of treatment. Docetaxel (DCT) and cisplatin (CDDP) doublet has been reported to be associated to a better QoL than the weekly vinorelbine (VNR) and CDDP regimen. Recently a newer more tolerated schedule of the VNR/CDDP regimen has been published and is widely employed in medical practice. The impact of these regimens on patients' QoL as well as symptoms control and type and grading chemo-related side-effects has been compared prospectically.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1872-8332
|
|
pubmed:author |
pubmed-author:BorsellinoNicolòN,
pubmed-author:CarrozzaFrancescoF,
pubmed-author:Caruso MMicheleM,
pubmed-author:CinieriSaverioS,
pubmed-author:ColucciGiuseppeG,
pubmed-author:FerraùFrancescoF,
pubmed-author:GalettaDomenicoD,
pubmed-author:GebbiaVittorioV,
pubmed-author:LeoSilvanaS,
pubmed-author:LorussoVitoV,
pubmed-author:MancarellaSergioS,
pubmed-author:MancusoGianfrancoG,
pubmed-author:PalombaGiuseppeG,
pubmed-author:RiccardiFernandoF
|
|
pubmed:copyrightInfo |
Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
69
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
218-24
|
|
pubmed:meshHeading |
pubmed-meshheading:19910076-Adult,
pubmed-meshheading:19910076-Aged,
pubmed-meshheading:19910076-Anemia,
pubmed-meshheading:19910076-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19910076-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:19910076-Cisplatin,
pubmed-meshheading:19910076-Clinical Protocols,
pubmed-meshheading:19910076-Disease Progression,
pubmed-meshheading:19910076-Female,
pubmed-meshheading:19910076-Humans,
pubmed-meshheading:19910076-Lung Neoplasms,
pubmed-meshheading:19910076-Male,
pubmed-meshheading:19910076-Middle Aged,
pubmed-meshheading:19910076-Neutropenia,
pubmed-meshheading:19910076-Quality of Life,
pubmed-meshheading:19910076-Survival Analysis,
pubmed-meshheading:19910076-Taxoids,
pubmed-meshheading:19910076-Vinblastine
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
|
|
pubmed:affiliation |
Medical Oncology Unit, University of Palermo, La Maddalena Clinic for Cancer, Palermo, Italy. vittorio.gebbia@tin.it
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
